735
Participants
Start Date
March 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
November 30, 2008
0.5mg DRSP / 0.5mg E2 (BAY86-4891)
One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
0.25mg DRSP / 0.5mg E2 (BAY86-4891)
One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Estradiol (E2 0.3mg)
One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
Placebo
Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Wexford
Pittsburgh
Erie
Philadelphia
Richmond
Norfolk
Winston-Salem
Raleigh
Columbia
Decatur
Atlanta
Atlanta
Daytona Beach
Jacksonville
Miami
Miami
West Palm Beach
Boynton Beach
Lake Worth
Tampa
Clearwater
Fort Myers
New Port Richey
Leesburg
Mobile
Chattanooga
Chattanooga
Memphis
Lexington
Columbus
Cleveland
Newburgh
Paw Paw
Chaska
Sioux Falls
Fargo
Billings
Billings
Arlington Heights
La Grange Park
Champaign
Springfield
Lincoln
Marrero
Amite
Little Rock
Oklahoma City
Tulsa
Dallas
Houston
Houston
Denver
Colorado Springs
Idaho Falls
Boise
Phoenix
Chandler
Tucson
Tucson
Albuquerque
Las Vegas
Reno
Paramount
Valley Village
Vista
San Diego
San Diego
San Diego
San Diego
Renton
Seattle
New Britain
Lawrenceville
New Brunswick
Princeton
Burlington
Lead Sponsor
Bayer
INDUSTRY